Alembic Share News - Latest Updates, Live News & More

Latest news about Alembic

Alembic Pharmaceuticals Q3FY26: Revenue Surges 11% to ₹1,876 Cr, Strong Growth Across Segments 3 hrs ago Today

Alembic Pharmaceuticals delivered strong Q3FY26 results with 11% revenue growth to ₹1,876 crore and 14% EBITDA growth to ₹308 crore. All business segments showed positive growth with Ex-US International leading at 36% growth, while the company received 7 ANDA approvals and maintained healthy margins despite recognizing a ₹42 crore one-time provision under new labour codes.

Alembic Pharmaceuticals Receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion Generic 9 days ago

Alembic Pharma Receives USFDA Tentative Approval for Bosutinib Cancer Treatment Drug Jan 12, 2026

Alembic Pharmaceuticals Receives USFDA Tentative Approval for 400 mg Bosutinib Tablets Jan 12, 2026

Alembic Pharmaceuticals Receives Final USFDA Approval for Travoprost Ophthalmic Solution Dec 18, 2025

More news about Alembic

11Dec 25

Alembic Pharmaceuticals Receives Final USFDA Approval for Ophthalmic Suspension

Alembic Pharmaceuticals announced final USFDA approval for its Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%, with Competitive Generic Therapy exclusivity for 180 days upon commercialization. The approved product is therapeutically equivalent to Bausch Lomb's Zylet Ophthalmic Suspension and expands the company's US regulatory portfolio to 231 total ANDA approvals.

17Nov 25

Alembic Pharmaceuticals Secures USFDA Approval for Hypertension Drug

Alembic Pharmaceuticals has received final approval from the USFDA for Diltiazem Hydrochloride Tablets in four different strengths. This cardiovascular drug is used to treat high blood pressure and angina. The approval brings Alembic's total ANDA approvals to 230. Despite this positive development, the company's stock closed 1.28% lower at Rs 904.20, with a year-to-date decline of 14.00%.

10Nov 25

Alembic Limited Reports Q2 FY26 Results: Consolidated Revenue Up 5.6%, Net Profit Rises 6.2%

Alembic Limited announced Q2 FY26 results with consolidated revenue increasing 5.6% to Rs 5,586.00 lakhs and net profit rising 6.2% to Rs 12,849.00 lakhs. EPS improved to Rs 5.00. The API business segment showed significant growth with 38.1% revenue increase, while the real estate segment remained stable. For H1 FY26, consolidated revenue reached Rs 10,561.00 lakhs, up 1.8%, and net profit increased 7.5% to Rs 19,013.00 lakhs. The company maintained a strong equity position with total equity of Rs 2,53,580.00 lakhs as of September 30, 2025.

05Nov 25

Alembic Pharma Targets 18-20% EBITDA Margins Through Production Ramp-Up and New Launches

Alembic Pharmaceuticals plans to increase EBITDA margins from 17% to 18-20% over the next few years. Strategies include enhancing production capacity, allocating Rs 400 crore for capex, and focusing on volume increases to counter U.S. market pricing pressures. The company plans to launch high-value products like complex injectables, peptides, and ophthalmic products in the U.S. market. Alembic is also targeting growth in non-U.S. markets for its generics segment. The stock price rose 2.79% to close at 950.00 on the NSE, reflecting positive market sentiment.

04Nov 25

Alembic Pharma Reports 21% Profit Growth; Shares Rise on Strong Q2 Performance

Alembic Pharmaceuticals posted impressive Q2 FY26 results, with consolidated net profit rising 21% to ₹185 crore and revenue increasing 16% to ₹1,910 crore. EBITDA grew 32% to ₹315.30 crore, with margin expanding to 16.50%. US generics business saw 21% growth, while ex-US international generics surged 31%. The company launched three new products in the US, received six ANDA approvals, and completed the acquisition of Utility Therapeutics. Shares traded 7.3% higher following the announcement.

29Oct 25

Alembic Pharma Secures USFDA Approval for Heart Medication, Expands Product Portfolio

Alembic Pharmaceuticals has received final approval from the USFDA for Ticagrelor tablets in 60mg strength. The medication, used to reduce cardiovascular risks, is equivalent to AstraZeneca's Brilinta Tablets. The market size for this product is estimated at $236.00 million for the 12 months ending June 2025. Alembic now holds 227 ANDA approvals from the USFDA. Despite this approval, the company's stock is trading flat at ₹905.15, with a year-to-date decline of 13.70%.

18Oct 25

Alembic Pharmaceuticals Secures USFDA Approval for Generic Triamcinolone Injectable

Alembic Pharmaceuticals has received final approval from the USFDA for its generic version of Triamcinolone Acetonide Injectable Suspension USP 40 mg/mL. This corticosteroid formulation is designed for joint-injection and intralesional administration. The approval marks Alembic's 206th final approval, bringing their total ANDA approvals to 227, including 21 tentative approvals. This milestone is expected to strengthen Alembic's position in the U.S. generics market, particularly in injectable medications, aligning with their strategy to expand market share in North American regulated markets.

25Sept 25

Alembic Pharma Secures USFDA Approval for Generic Antidepressant

Alembic Pharmaceuticals has obtained final USFDA approval for its generic version of Paroxetine extended-release tablets in 25 mg and 37.5 mg strengths. The product is therapeutically equivalent to Apotex Inc's Paxil CR and is indicated for treating major depressive disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder. This approval is expected to strengthen Alembic's position in the US generic drug market and increase access to affordable mental health medications.

19Sept 25

Alembic Limited Shareholders Approve Udit Amin as Managing Director with Overwhelming Support

Alembic Limited's shareholders have overwhelmingly approved the appointment of Mr. Udit Amin as the new Managing Director through a postal ballot conducted via remote e-voting. The special resolution passed with 98.90% of votes in favor, with 19,19,80,794 total votes cast. The Promoter and Promoter Group showed 100% support, while public institutions largely voted against the resolution. The voting process, open for 30 days, was scrutinized and confirmed to comply with all relevant regulations.

15Sept 25

Alembic Pharma Receives FDA Inspection Report for Two API Facilities

Alembic Pharmaceuticals Limited has received an Establishment Inspection Report (EIR) from the U.S. FDA for its API-I and API-II facilities in Panelav. The inspection was conducted from May 26th to May 31st. This EIR signifies successful closure of the inspection and compliance with current Good Manufacturing Practices (cGMP). The development is expected to reinforce regulatory compliance, boost market confidence, and potentially support future drug applications and API manufacturing for the U.S. market.

13Sept 25

Alembic Pharma Secures USFDA Clearance for Panelav Facilities, Reports 15% Profit Growth

Alembic Pharmaceuticals received Establishment Inspection Reports (EIRs) from USFDA for its API-I and API-II facilities in Panelav, Gujarat. The company also got USFDA approval for Macitentan Tablets. Financially, Alembic reported a 15% increase in net profit to ₹154 crore, 10% revenue growth to ₹1,711 crore, and improved EBITDA margin of 16.50% in the latest quarter.

05Sept 25

Alembic Limited Sets Book Closure Dates for Dividend and AGM

Alembic Limited has set book closure dates from July 31 to August 6, 2021, for determining shareholder eligibility for dividend payment and participation in the Annual General Meeting (AGM) for FY 2020-21. The closure of the Register of Members and Share Transfer Books during this period will establish the list of shareholders eligible for these corporate actions.

19Aug 25

Alembic Limited Seeks Shareholder Approval for Udit Amin's Appointment as Managing Director

Alembic Limited seeks shareholder approval for appointing Udit Amin as Managing Director for a five-year term starting October 1, 2025. The proposed remuneration package includes a maximum CTC of Rs. 10.00 crore per annum. Amin, with over 22 years of industry experience, is currently a Non-Executive Non-Independent Director. The appointment requires shareholder approval through e-voting and Central Government approval due to Amin's NRI status. Current Managing Director & CEO, Mrs. Malika Amin, will step down and transition to a Non-Executive role.

19Aug 25

Glenmark Pharmaceuticals Among Three Indian Firms Recalling Products in US Market

Alembic Pharmaceuticals, Glenmark Pharmaceuticals, and Sun Pharmaceutical Industries are recalling multiple products from the US market due to manufacturing defects. Glenmark is recalling 73,056 units of Carvedilol Tablets and 22,656 bottles of Theophylline Extended-Release Tablets. Alembic is recalling 9,492 bottles of Doxepin Hydrochloride capsules, while Sun Pharma's US arm is recalling 11,328 bottles of Spironolactone tablets. The recalls, classified as Class II by the FDA, are due to issues such as nitrosamine impurity levels and contamination with aluminum.

16Aug 25

Alembic Pharma Secures USFDA Approval for Tretinoin Cream 0.025%

Alembic Pharmaceuticals has received final approval from the USFDA for Tretinoin Cream 0.025%, a topical medication used in dermatology. This approval allows the company to market and distribute the product in the United States, potentially expanding its dermatological portfolio and strengthening its position in the U.S. pharmaceutical market. The approval is expected to contribute to revenue growth and enhance Alembic's market presence.

12Aug 25

Alembic Reports Q1 Profit Growth Amid Revenue Dip; Announces Leadership Changes

Alembic Limited's Q1 consolidated net profit increased by 2.30% to ₹178.00 crore, while revenue declined by 2.17% to ₹497.00 crore. EBITDA decreased to ₹196.00 crore with a margin of 39.44%. The API segment showed growth with revenue of ₹129.50 crore, while the Real Estate segment declined to ₹368.00 crore. The company announced leadership changes with Mr. Udit Amin appointed as Managing Director effective October 1, 2025, and Mrs. Malika Amin resigning as MD & CEO effective January 1, 2026.

05Aug 25

Alembic Pharma Reports 15% Jump in Q1 Net Profit, Revenue Grows 10%

Alembic Pharmaceuticals posted robust Q1 FY24 results. Net profit increased by 15% to ₹154.00 crore, while revenue grew 10% to ₹1,711.00 crore year-on-year. EBITDA rose 19% to ₹282.00 crore, with EBITDA margin expanding by 130 bps to 16.50%. Despite positive financials, the company's stock traded flat at ₹968.75, with an 8% year-to-date decline.

26Jul 25

Alembic Pharma Secures USFDA Approval for Carbamazepine Extended Release Tablets

Alembic Pharmaceuticals received final USFDA approval for Carbamazepine extended release tablets in 100mg, 200mg, and 400mg strengths. The drug, equivalent to Novartis' Tegretol-XR, is used as an anti-convulsant and for treating trigeminal neuralgia pain. The estimated market size for these tablets is $71.00 million for the 12 months ending March 2025. This approval brings Alembic's total ANDA approvals to 225, including 202 final and 23 tentative approvals. Despite the news, Alembic's shares closed 1.91% lower at ₹999.00.

13May 25

Alembic Reports Q4 Profit Growth and Announces Dividend

Alembic Pharmaceuticals has released its Q4 financial results, showing significant growth. Net profit increased by 11.8% to ₹238.00 crore, while revenue grew by 23% to ₹603.00 crore. EBITDA rose by 13% to ₹273.00 crore, although the EBITDA margin slightly decreased. The company's board has recommended a dividend of ₹2.40 per equity share.